GlassScriptPhysician profile
Ashlie Krajewski
NPI 1407202260
$5,350.86
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $467 · 2020: $999 · 2021: $1,363 · 2022: $1,735 · 2023: $786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $786.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,283.10 | 2021-2023 | |
| Novo Nordisk INC | $546.16 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $379.14 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $355.64 | 2019-2022 | |
| Allergan, INC. | $298.23 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $247.50 | 2021-2023 | |
| Lilly USA, LLC | $245.25 | 2019-2023 | Mounjaro, Taltz |
| Esperion Therapeutics, INC. | $228.41 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $209.27 | 2019-2023 | Belsomra, Steglatro |
| Amarin Pharma, INC. | $190.68 | 2019-2023 | |
| Abbott Laboratories | $145.68 | 2021-2023 | Freestyle Libre 3 |
| Boston Scientific Corporation | $135.29 | 2020 | |
| Gilead Sciences, INC. | $121.80 | 2021-2023 | |
| Amgen INC. | $109.80 | 2020-2023 | Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.94 | 2019-2023 | Xifaxan |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $81.99 | 2019-2022 | |
| Glaxosmithkline, LLC. | $73.76 | 2019-2023 | Shingrix |
| Dexcom, INC. | $65.85 | 2022-2023 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $65.51 | 2022 | |
| Edwards Lifesciences Corporation | $61.83 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $60.76 | 2021 | |
| Axsome Therapeutics, INC. | $47.44 | 2022-2023 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.11 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $45.14 | 2022-2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $42.01 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.88 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.42 | 2022-2023 | |
| Supernus Pharmaceuticals, INC. | $39.14 | 2022 | |
| Daiichi Sankyo INC. | $14.90 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.79 | 2023 | Quviviq |
| Insulet Corporation | $13.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashlie Krajewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.